New hope for tough blood cancers: experimental drug AC676 enters human testing
Disease control
Recruiting now
This early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like leukemia or lymphoma) that returned or didn't respond to prior treatments. The main goals are to find a safe dose and understand side effects. Researchers will also check how …
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC